A Two-Gene Prognostic Classifier for Early-Stage Lung Squamous Cell Carcinoma in Multiple Large-Scale and Geographically Diverse Cohorts

Journal of Thoracic Oncology

Volumn 12, Issue 1, 2017, Pages 65-76

  Noro, Rintaro ^a   Ishigame, Teruhide ^a   Walsh, Naomi ^a   Shiraishi, Kouya ^b   Robles, Ana I ^a   Ryan, Bríd M ^a   Schetter, Aaron J ^a   Bowman, Elise D ^a   Welsh, Judith A ^a   Seike, Masahiro ^c   Gemma, Akihiko ^c   Skaug, Vidar ^d   Mollerup, Steen ^d   Haugen, Aage ^d   Yokota, Jun ^e   Kohno, Takashi ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

^e Institute of Predictive and Personalized Medicine of Cancer   (Spain)

Author keywords

Biomarker; Gene expression; Lung squamous cell carcinoma; Microarray; Prognostic classifier

Indexed keywords

ALPHA ACTININ 4; DUAL SPECIFICITY PHOSPHATASE 6; TUMOR MARKER;

ACTN4 GENE; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLASSIFIER; COHORT ANALYSIS; CONTROLLED STUDY; DUSP6 GENE; FEMALE; GENE EXPRESSION PROFILING; GENETIC SELECTION; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; RECURRENCE RISK; SCORING SYSTEM; SQUAMOUS CELL LUNG CARCINOMA; TUMOR GENE; CLINICAL TRIAL; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 85015344629     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.08.141     Document Type: Article

References (49)

1. 1 Torre, L.A., Bray, F., Siegel, R.L., et al. Global cancer statistics, 2012. CA Cancer J Clin 65 (2015), 87–108.
2. 2 Travis, W.D., Pathology of lung cancer. Clin Chest Med 32 (2011), 669–692.
3. 3 Pesch, B., Kendzia, B., Gustavsson, P., et al. Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 131 (2012), 1210–1219.
4. 4 Young, R.P., Hopkins, R.J., Christmas, T., et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 34 (2009), 380–386.
5. 5 Tammemagi, C.M., Neslund-Dudas, C., Simoff, M., et al. Impact of comorbidity on lung cancer survival. Int J Cancer 103 (2003), 792–802.
6. 6 Papi, A., Casoni, G., Caramori, G., et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. Thorax 59 (2004), 679–681.
7. 7 National Lung Screening Trial Research Team, Aberle, D.R., Adams, A.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365 (2011), 395–409.
8. 8 Wilson, D.O., Ryan, A., Fuhrman, C., et al. Doubling times and CT screen-detected lung cancers in the Pittsburgh Lung Screening Study. Am J Respir Crit Care Med 185 (2012), 85–89.
9. 9 Pinsky, P.F., Church, T.R., Izmirlian, G., et al. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 119 (2013), 3976–3983.
10. 10 Chansky, K., Sculier, J.P., Crowley, J.J., et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4 (2009), 792–801.
11. 11 Pignon, J.P., Tribodet, H., Scagliotti, G.V., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26 (2008), 3552–3559.
12. 12 Subramanian, J., Simon, R., Gene expression-based prognostic signatures in lung cancer: ready for clinical use?. J Natl Cancer Inst 102 (2010), 464–474.
13. 13 Okayama, H., Schetter, A.J., Ishigame, T., et al. The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts. Cancer Epidemiol Biomarkers Prev 23 (2014), 2884–2894.
14. 14 Akagi, I., Okayama, H., Schetter, A.J., et al. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma. Cancer Res 73 (2013), 3821–3832.
15. 15 Virtanen, C., Ishikawa, Y., Honjoh, D., et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci U S A 99 (2002), 12357–12362.
16. 16 Khuder, S.A., Mutgi, A.B., Effect of smoking cessation on major histologic types of lung cancer. Chest 120 (2001), 1577–1583.
17. 17 Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer. N Engl J Med 359 (2008), 1367–1380.
18. 18 Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511 (2014), 543–550.
19. 19 Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489 (2012), 519–525.
20. 20 Bozinovski, S., Vlahos, R., Anthony, D., et al. COPD and squamous cell lung cancer: aberrant inflammation and immunity is the common link. Br J Pharmacol 173 (2015), 635–648.
21. 21 Lau, S.K., Boutros, P.C., Pintilie, M., et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 25 (2007), 5562–5569.
22. 22 Gandara, D.R., Hammerman, P.S., Sos, M.L., et al. Squamous cell lung cancer: from tumor genomics to cancer therapeutics. Clin Cancer Res 21 (2015), 2236–2243.
23. 23 Altman, D.G., McShane, L.M., Sauerbrei, W., et al. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. BMC Med, 10, 2012, 51.
24. 24 National Center for Biotechnology Information. Gene Expression Omnibus. http://www.ncbi.nlm.nih.gov/geo/. Accessed June 1, 2015.
25. 25 Higgins, J.P., Thompson, S.G., Deeks, J.J., et al. Measuring inconsistency in meta-analyses. BMJ 327 (2003), 557–560.
26. 26 Iontorrent by Thermo Fischer Scientific. ONCOAMINE v.4.5: 729 Datasets and 91,866 Samples. http://www.oncomine.com. Accessed June 1, 2015.
27. 27 Lee, E.S., Son, D.S., Kim, S.H., et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 14 (2008), 7397–7404.
28. 28 Sato, M., Larsen, J.E., Lee, W., et al. Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations. Mol Cancer Res 11 (2013), 638–650.
29. 29 Rousseaux, S., Debernardi, A., Jacquiau, B., et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med, 5, 2013 186ra166.
30. 30 Botling, J., Edlund, K., Lohr, M., et al. Biomarker discovery in non-small cell lung cancer: integrating gene expression profiling, meta-analysis, and tissue microarray validation. Clin Cancer Res 19 (2013), 194–204.
31. 31 Bild, A.H., Yao, G., Chang, J.T., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439 (2006), 353–357.
32. 32 Raponi, M., Zhang, Y., Yu, J., et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66 (2006), 7466–7472.
33. 33 Chen, H.Y., Yu, S.L., Chen, C.H., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356 (2007), 11–20.
34. 34 Yang, B., Tan, Y., Sun, H., et al. Higher intratumor than peritumor expression of DUSP6/MKP-3 is associated with recurrence after curative resection of hepatocellular carcinoma. Chin Med J (Engl) 127 (2014), 1211–1217.
35. 35 Messina, S., Frati, L., Leonetti, C., et al. Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene 30 (2011), 3813–3820.
36. 36 Degl'Innocenti, D., Romeo, P., Tarantino, E., et al. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells. Endocr Relat Cancer 20 (2013), 23–37.
37. 37 Bagnyukova, T.V., Restifo, D., Beeharry, N., et al. DUSP6 regulates drug sensitivity by modulating DNA damage response. Br J Cancer 109 (2013), 1063–1071.
38. 38 Song, H., Wu, C., Wei, C., et al. Silencing of DUSP6 gene by RNAi-mediation inhibits proliferation and growth in MDA-MB-231 breast cancer cells: an in vitro study. Int J Clin Exp Med 8 (2015), 10481–10490.
39. 39 Wang, M.C., Chang, Y.H., Wu, C.C., et al. Alpha-actinin 4 is associated with cancer cell motility and is a potential biomarker in non-small cell lung cancer. J Thorac Oncol 10 (2015), 286–301.
40. 40 Koizumi, T., Nakatsuji, H., Fukawa, T., et al. The role of actinin-4 in bladder cancer invasion. Urology 75 (2010), 357–364.
41. 41 Honda, K., The biological role of actinin-4 (ACTN4) in malignant phenotypes of cancer. Cell Biosci, 5, 2015, 41.
42. 42 Gao, Y., Li, G., Sun, L., et al. ACTN4 and the pathways associated with cell motility and adhesion contribute to the process of lung cancer metastasis to the brain. BMC Cancer, 15, 2015, 277.
43. 43 Yamamoto, S., Tsuda, H., Honda, K., et al. Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol 22 (2009), 499–507.
44. 44 Yamagata, N., Shyr, Y., Yanagisawa, K., et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 9 (2003), 4695–4704.
45. 45 Watanabe, T., Ueno, H., Watabe, Y., et al. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer. Br J Cancer 112 (2015), 704–713.
46. 46 Zhai, R., Yu, X., Shafer, A., et al. The impact of coexisting COPD on survival of patients with early-stage non-small cell lung cancer undergoing surgical resection. Chest 145 (2014), 346–353.
47. 47 Hanagiri, T., Sugio, K., Mizukami, M., et al. Significance of smoking as a postoperative prognostic factor in patients with non-small cell lung cancer. J Thorac Oncol 3 (2008), 1127–1132.
48. 48 Putila, J., Guo, N.L., Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer. PLoS One, 9, 2014, e100994.
49. 49 Robles, A.I., Arai, E., Mathe, E.A., et al. An integrated prognostic classifier for stage I lung adenocarcinoma based on mRNA, microRNA, and DNA methylation biomarkers. J Thorac Oncol 10 (2015), 1037–1048.